FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:92-98 January 10, 2002 Number 2 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Carney, D. N. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background We conducted a randomized study to determine whether any of three chemotherapy regimens was superior to cisplatin and paclitaxel in patients with advanced non–small-cell lung cancer.

Methods A total of 1207 patients with advanced non–small-cell lung cancer were randomly assigned to a reference regimen of cisplatin and paclitaxel or to one of three experimental regimens: cisplatin and gemcitabine, cisplatin and docetaxel, or carboplatin and paclitaxel.

Results The response rate for all 1155 eligible patients was 19 percent, with a median survival of 7.9 months (95 percent confidence interval, 7.3 to 8.5), a 1-year survival rate of 33 percent (95 percent confidence interval, 30 to 36 percent), and a 2-year survival rate of 11 percent (95 percent confidence interval, 8 to 12 percent). The response rate and survival did not differ significantly between patients assigned to receive cisplatin and paclitaxel and those assigned to receive any of the three experimental regimens. Treatment with cisplatin and gemcitabine was associated with a significantly longer time to the progression of disease than was treatment with cisplatin and paclitaxel but was more likely to cause grade 3, 4, or 5 renal toxicity (in 9 percent of patients, vs. 3 percent of those treated with cisplatin plus paclitaxel). Patients with a performance status of 2 had a significantly lower rate of survival than did those with a performance status of 0 or 1.

Conclusions None of four chemotherapy regimens offered a significant advantage over the others in the treatment of advanced non–small-cell lung cancer.

Source Information

From the University of Wisconsin Hospital and Clinics, Madison (J.H.S.); the Dana–Farber Cancer Institute, Boston (D.H., J.Z.); the University of Pittsburgh Cancer Institute, Pittsburgh (C.P.B.); the Fox Chase Cancer Center, Philadelphia (C.L.); Indiana University, Indianapolis (A.S.); the Duluth Clinic, Duluth, Minn. (J.K.); and Vanderbilt University, Nashville (D.H.J.).

Full Text of this Article

This article has been cited by other articles:

• Gronberg, B. H., Bremnes, R. M., Flotten, O., Amundsen, T., Brunsvig, P. Fr., Hjelde, H. H., Kaasa, S., von Plessen, C., Stornes, F., Tollali, T., Wammer, F., Aasebo, U., Sundstrom, S. (2009). Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared With Gemcitabine Plus Carboplatin As First-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer. JCO 27: 3217-3224 [Abstract] [Full Text]  
• Tan, E. H., Rolski, J., Grodzki, T., Schneider, C. P., Gatzemeier, U., Zatloukal, P., Aitini, E., Carteni, G., Riska, H., Tsai, Y. H., Abratt, R. (2009). Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol 20: 1249-1256 [Abstract] [Full Text]  
• Kim, Y. H., Kubota, K., Goto, K., Yoh, K., Niho, S., Ohmatsu, H., Saijo, N., Nishiwaki, Y. (2009). A Phase I Study of Gemcitabine and Carboplatin in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2. Jpn J Clin Oncol 0: hyp061v1-hyp061 [Abstract] [Full Text]  
• Naoki, K., Kunikane, H., Fujii, T., Tsujimura, S., Hida, N., Okamoto, H., Watanabe, K. (2009). Dose-escalating and Pharmacokinetic Study of a Weekly Combination of Paclitaxel and Carboplatin for Inoperable Non-small Cell Lung Cancer: JCOG 9910-DI. Jpn J Clin Oncol 0: hyp059v1-hyp059 [Abstract] [Full Text]  
• Rossi, G., Pelosi, G., Graziano, P., Barbareschi, M., Papotti, M. (2009). Review Article: A Reevaluation of the Clinical Significance of Histological Subtyping of Non--Small-Cell Lung Carcinoma: Diagnostic Algorithms in the Era of Personalized Treatments. INT J SURG PATHOL 17: 206-218 [Abstract]  
• Steger, V., Walles, T., Kosan, B., Walker, T., Kyriss, T., Veit, S., Dippon, J., Friedel, G. (2009). Trimodal Therapy for Histologically Proven N2/3 Non-Small Cell Lung Cancer: Mid-Term Results and Indicators for Survival.. Ann. Thorac. Surg. 87: 1676-1683 [Abstract] [Full Text]  
• Socinski, M. A., Saleh, M. N., Trent, D. F., Dobbs, T. W., Zehngebot, L. M., Levine, M. A., Bordoni, R., Stella, P. J. (2009). A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC). Ann Oncol 20: 1068-1073 [Abstract] [Full Text]  
• RICE, S. D., BUSH, J. E., BROWER, S. L. (2009). Assessment of Erlotinib in Chemoresponse Assay. Anticancer Res 29: 1993-1997 [Abstract] [Full Text]  
• Papadaki, C., Mavroudis, D., Trypaki, M., Koutsopoulos, A., Stathopoulos, E., Hatzidaki, D., Tsakalaki, E., Georgoulias, V., Souglakos, J. (2009). Tumoral Expression of TXR1 and TSP1 Predicts Overall Survival of Patients with Lung Adenocarcinoma Treated with First-line Docetaxel-Gemcitabine Regimen. Clin. Cancer Res. 15: 3827-3833 [Abstract] [Full Text]  
• Natale, R. B., Bodkin, D., Govindan, R., Sleckman, B. G., Rizvi, N. A., Capo, A., Germonpre, P., Eberhardt, W. E.E., Stockman, P. K., Kennedy, S. J., Ranson, M. (2009). Vandetanib Versus Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study. JCO 27: 2523-2529 [Abstract] [Full Text]  
• Feng, J., Sun, X., Sun, N., Qin, S., Li, F., Cheng, H., Chen, B., Cao, Y., Ma, J., Cheng, L., Lu, Z., Ji, J., Zhou, Y. (2009). XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer. Acta Biochim Biophys Sin 41: 429-435 [Abstract] [Full Text]  
• Goss, G., Ferry, D., Wierzbicki, R., Laurie, S. A., Thompson, J., Biesma, B., Hirsch, F. R., Varella-Garcia, M., Duffield, E., Ataman, O. U., Zarenda, M., Armour, A. A. (2009). Randomized Phase II Study of Gefitinib Compared With Placebo in Chemotherapy-Naive Patients With Advanced Non-Small-Cell Lung Cancer and Poor Performance Status. JCO 27: 2253-2260 [Abstract] [Full Text]  
• West, H. L., Wakelee, H. A., Perry, M. C., Belt, R. J., Chen, R., Obasaju, C. (2009). Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial. Ann Oncol 20: 850-856 [Abstract] [Full Text]  
• HIROSE, T., SUGIYAMA, T., KUSUMOTO, S., SHIRAI, T., NAKASHIMA, M., YAMAOKA, T., OKUDA, K., OGURA, K., OHNISHI, T., OHMORI, T., ADACHI, M. (2009). Phase II Study of the Combination of Nedaplatin and Weekly Paclitaxel in Patients with Advanced Non-small Cell Lung Cancer. Anticancer Res 29: 1733-1738 [Abstract] [Full Text]  
• Grossi, F., Aita, M., Defferrari, C., Rosetti, F., Brianti, A., Fasola, G., Vinante, O., Pronzato, P., Pappagallo, G. (2009). Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach. The Oncologist 14: 497-510 [Abstract] [Full Text]  
• Horn, L., Sandler, A. B. (2009). Angiogenesis in the Treatment of Non-Small Cell Lung Cancer. Proc Am Thorac Soc 6: 206-217 [Abstract] [Full Text]  
• Stinchcombe, T. E., Socinski, M. A. (2009). Current Treatments for Advanced Stage Non-Small Cell Lung Cancer. Proc Am Thorac Soc 6: 233-241 [Abstract] [Full Text]  
• Kuang, Y., Rogers, A., Yeap, B. Y., Wang, L., Makrigiorgos, M., Vetrand, K., Thiede, S., Distel, R. J., Janne, P. A. (2009). Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non-Small Cell Lung Cancer. Clin. Cancer Res. 15: 2630-2636 [Abstract] [Full Text]  
• Sculier, J-P., Moro-Sibilot, D. (2009). First- and second-line therapy for advanced nonsmall cell lung cancer. Eur Respir J 33: 915-930 [Abstract] [Full Text]  
• Sun, Q., Liu, C., Zhong, H., Zhong, B., Xu, H., Shen, W., Wang, D. (2009). Multi-center Phase II Trial of Weekly Paclitaxel Plus Cisplatin Combination Chemotherapy in Patients with Advanced Gastric and Gastro-esophageal Cancer. Jpn J Clin Oncol 39: 237-243 [Abstract] [Full Text]  
• Barros Costa, R. L. (2009). Review Article: Targeted Therapy: Comprehensive Review. AM J HOSP PALLIAT CARE 26: 137-146 [Abstract]  
• Allen-Auerbach, M., Weber, W. A. (2009). Measuring Response with FDG-PET: Methodological Aspects. The Oncologist 14: 369-377 [Abstract] [Full Text]  
• Hsu, D. S., Acharya, C. R., Balakumaran, B. S., Riedel, R. F., Kim, M. K., Stevenson, M., Tuchman, S., Mukherjee, S., Barry, W., Dressman, H. K., Nevins, J. R., Powers, S., Mu, D., Potti, A. (2009). Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer. Proc. Natl. Acad. Sci. USA 106: 5312-5317 [Abstract] [Full Text]  
• Inoue, A., Kobayashi, K., Usui, K., Maemondo, M., Okinaga, S., Mikami, I., Ando, M., Yamazaki, K., Saijo, Y., Gemma, A., Miyazawa, H., Tanaka, T., Ikebuchi, K., Nukiwa, T., Morita, S., Hagiwara, K. (2009). First-Line Gefitinib for Patients With Advanced Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy. JCO 27: 1394-1400 [Abstract] [Full Text]  
• Langer, C. J. (2009). The "Lazarus Response" in Treatment-Naive, Poor Performance Status Patients With Non-Small-Cell Lung Cancer and Epidermal Growth Factor Receptor Mutation. JCO 27: 1350-1354 [Full Text]  
• Yung, T. K.F., Chan, K.C. A., Mok, T. S.K., Tong, J., To, K.-F., Lo, Y.M. D. (2009). Single-Molecule Detection of Epidermal Growth Factor Receptor Mutations in Plasma by Microfluidics Digital PCR in Non-Small Cell Lung Cancer Patients. Clin. Cancer Res. 15: 2076-2084 [Abstract] [Full Text]  
• Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N., Manegold, C. (2009). Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL. JCO 27: 1227-1234 [Abstract] [Full Text]  
• Motohashi, S., Nagato, K., Kunii, N., Yamamoto, H., Yamasaki, K., Okita, K., Hanaoka, H., Shimizu, N., Suzuki, M., Yoshino, I., Taniguchi, M., Fujisawa, T., Nakayama, T. (2009). A Phase I-II Study of {alpha}-Galactosylceramide-Pulsed IL-2/GM-CSF-Cultured Peripheral Blood Mononuclear Cells in Patients with Advanced and Recurrent Non-Small Cell Lung Cancer. J. Immunol. 182: 2492-2501 [Abstract] [Full Text]  
• Hsieh, W.-C., Cheng, Y.-W., Lin, C.-J., Chou, M.-C., Chen, C.-Y., Lee, H. (2009). Prognostic Significance of X-ray Cross-complementing Group 1 T-77C Polymorphism in Resected Non-small Cell Lung Cancer. Jpn J Clin Oncol 39: 81-85 [Abstract] [Full Text]  
• Fidias, P. M., Dakhil, S. R., Lyss, A. P., Loesch, D. M., Waterhouse, D. M., Bromund, J. L., Chen, R., Hristova-Kazmierski, M., Treat, J., Obasaju, C. K., Marciniak, M., Gill, J., Schiller, J. H. (2009). Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non-Small-Cell Lung Cancer. JCO 27: 591-598 [Abstract] [Full Text]  
• Crabb, S. J., Patsios, D., Sauerbrei, E., Ellis, P. M., Arnold, A., Goss, G., Leighl, N. B., Shepherd, F. A., Powers, J., Seymour, L., Laurie, S. A. (2009). Tumor Cavitation: Impact on Objective Response Evaluation in Trials of Angiogenesis Inhibitors in Non-Small-Cell Lung Cancer. JCO 27: 404-410 [Abstract] [Full Text]  
• Extermann, M., Muss, H. B. (2009). Conducting Clinical Trials for Patients Who Are Frail or Elderly. Am Soc Clin Oncol Ed Book 2009: 289-293 [Abstract] [Full Text]  
• Kim, H.-T., Lee, J.-E., Shin, E.-S., Yoo, Y.-K., Cho, J.-H., Yun, M.-H., Kim, Y.-H., Kim, S.-K., Kim, H.-J., Jang, T.-W., Kwak, S.-M., Kim, C.-S., Ryu, J.-S. (2008). Effect of BRCA1 Haplotype on Survival of Non-Small-Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy. JCO 26: 5972-5979 [Abstract] [Full Text]  
• Soda, M., Takada, S., Takeuchi, K., Choi, Y. L., Enomoto, M., Ueno, T., Haruta, H., Hamada, T., Yamashita, Y., Ishikawa, Y., Sugiyama, Y., Mano, H. (2008). A mouse model for EML4-ALK-positive lung cancer. Proc. Natl. Acad. Sci. USA 105: 19893-19897 [Abstract] [Full Text]  
• Scagliotti, G. V., Sugarman, K. P. (2008). In Reply. JCO 26: 5651-5652 [Full Text]  
• Yano, S., Wang, W., Li, Q., Matsumoto, K., Sakurama, H., Nakamura, T., Ogino, H., Kakiuchi, S., Hanibuchi, M., Nishioka, Y., Uehara, H., Mitsudomi, T., Yatabe, Y., Nakamura, T., Sone, S. (2008). Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations. Cancer Res. 68: 9479-9487 [Abstract] [Full Text]  
• Strauss, G. M., Herndon, J. E. II, Maddaus, M. A., Johnstone, D. W., Johnson, E. A., Harpole, D. H., Gillenwater, H. H., Watson, D. M., Sugarbaker, D. J., Schilsky, R. L., Vokes, E. E., Green, M. R. (2008). Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non-Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. JCO 26: 5043-5051 [Abstract] [Full Text]  
• Hernandez, A. M., Toledo, D., Martinez, D., Grinan, T., Brito, V., Macias, A., Alfonso, S., Rondon, T., Suarez, E., Vazquez, A. M., Perez, R. (2008). Characterization of the Antibody Response against NeuGcGM3 Ganglioside Elicited in Non-Small Cell Lung Cancer Patients Immunized with an Anti-Idiotype Antibody. J. Immunol. 181: 6625-6634 [Abstract] [Full Text]  
• Ko, J.-C., Hong, J.-H., Wang, L.-H., Cheng, C.-M., Ciou, S.-C., Lin, S.-T., Jheng, M.-Y., Lin, Y.-W. (2008). Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells. Molecular Cancer Therapeutics 7: 3632-3641 [Abstract] [Full Text]  
• de Langen, A. J., Lubberink, M., Boellaard, R., Spreeuwenberg, M. D., Smit, E. F., Hoekstra, O. S., Lammertsma, A. A. (2008). Reproducibility of Tumor Perfusion Measurements Using 15O-Labeled Water and PET. JNM 49: 1763-1768 [Abstract] [Full Text]  
• Chin, T. M., Quinlan, M. P., Singh, A., Sequist, L. V., Lynch, T. J., Haber, D. A., Sharma, S. V., Settleman, J. (2008). Reduced Erlotinib Sensitivity of Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer following Cisplatin Exposure: A Cell Culture Model of Second-line Erlotinib Treatment. Clin. Cancer Res. 14: 6867-6876 [Abstract] [Full Text]  
• Costa, D. B., Nguyen, K.-S. H., Cho, B. C., Sequist, L. V., Jackman, D. M., Riely, G. J., Yeap, B. Y., Halmos, B., Kim, J. H., Janne, P. A., Huberman, M. S., Pao, W., Tenen, D. G., Kobayashi, S. (2008). Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib. Clin. Cancer Res. 14: 7060-7067 [Abstract] [Full Text]  
• Berhoune, M., Banu, E., Scotte, F., Prognon, P., Oudard, S., Bonan, B. (2008). Therapeutic Strategy for Treatment of Metastatic Non-Small Cell Lung Cancer. The Annals of Pharmacotherapy 42: 1640-1652 [Abstract] [Full Text]  
• Herbst, R. S., Sandler, A. (2008). Bevacizumab and Erlotinib: A Promising New Approach to the Treatment of Advanced NSCLC. The Oncologist 13: 1166-1176 [Abstract] [Full Text]  
• Janne, P. A. (2008). Gefitinib First or Gefitinib Second: Is Timing Everything in the Treatment of EGFR Mutant Non-Small Cell Lung Cancer?. Am. J. Respir. Crit. Care Med. 178: 783-785 [Full Text]  
• von Plessen, C, Strand, T-E, Wentzel-Larsen, T, Omenaas, E, Wilking, N, Sundstrom, S, Sorenson, S (2008). Effectiveness of third-generation chemotherapy on the survival of patients with advanced non-small cell lung cancer in Norway: a national study. Thorax 63: 866-871 [Abstract] [Full Text]  
• Field, J. K. (2008). Lung Cancer Risk Models Come of Age. Cancer Prevention Research 1: 226-228 [Full Text]  
• Kawata, E., Ashihara, E., Kimura, S., Takenaka, K., Sato, K., Tanaka, R., Yokota, A., Kamitsuji, Y., Takeuchi, M., Kuroda, J., Tanaka, F., Yoshikawa, T., Maekawa, T. (2008). Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer. Molecular Cancer Therapeutics 7: 2904-2912 [Abstract] [Full Text]  
• Stinchcombe, T. E., Socinski, M. A. (2008). Gefitinib in Advanced Non-Small Cell Lung Cancer: Does It Deserve a Second Chance?. The Oncologist 13: 933-944 [Abstract] [Full Text]  
• Manegold, C., Gravenor, D., Woytowitz, D., Mezger, J., Hirsh, V., Albert, G., Al-Adhami, M., Readett, D., Krieg, A. M., Leichman, C. G. (2008). Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non-Small-Cell Lung Cancer. JCO 26: 3979-3986 [Abstract] [Full Text]  
• Okamoto, I., Nishimura, T., Miyazaki, M., Yoshioka, H., Kubo, A., Takeda, K., Ebi, N., Sugawara, S., Katakami, N., Fukuoka, M., Nakagawa, K. (2008). Phase II Study of Combination Therapy with S-1 and Irinotecan for Advanced Non-Small Cell Lung Cancer: West Japan Thoracic Oncology Group 3505. Clin. Cancer Res. 14: 5250-5254 [Abstract] [Full Text]  
• Flaherty, K. T., Schiller, J., Schuchter, L. M., Liu, G., Tuveson, D. A., Redlinger, M., Lathia, C., Xia, C., Petrenciuc, O., Hingorani, S. R., Jacobetz, M. A., Van Belle, P. A., Elder, D., Brose, M. S., Weber, B. L., Albertini, M. R., O'Dwyer, P. J. (2008). A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel. Clin. Cancer Res. 14: 4836-4842 [Abstract] [Full Text]  
• Chee, K. G., Nguyen, D. V., Brown, M., Gandara, D. R., Wun, T., Lara, P. N. Jr (2008). Positron Emission Tomography and Improved Survival in Patients With Lung Cancer: The Will Rogers Phenomenon Revisited. Arch Intern Med 168: 1541-1549 [Abstract] [Full Text]  
• Schiller, J. H. (2008). Noninvasive Monitoring of Tumors. NEJM 359: 418-420 [Full Text]  
• Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., Lee, J. S., Mellemgaard, A., Park, K., Patil, S., Rolski, J., Goksel, T., de Marinis, F., Simms, L., Sugarman, K. P., Gandara, D. (2008). Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer. JCO 26: 3543-3551 [Abstract] [Full Text]  
• Ko, J.-C., Ciou, S.-C., Cheng, C.-M., Wang, L.-H., Hong, J.-H., Jheng, M.-Y., Ling, S.-T., Lin, Y.-W. (2008). Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells. Carcinogenesis 29: 1448-1458 [Abstract] [Full Text]  
• Miyanaga, A., Gemma, A., Noro, R., Kataoka, K., Matsuda, K., Nara, M., Okano, T., Seike, M., Yoshimura, A., Kawakami, A., Uesaka, H., Nakae, H., Kudoh, S. (2008). Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model. Molecular Cancer Therapeutics 7: 1923-1930 [Abstract] [Full Text]  
• Hoskin, P. (2008). Opioids in context: relieving the pain of cancer. The role of comprehensive cancer management. Palliat Med 22: 303-309 [Abstract]  
• Sequist, L. V., Martins, R. G., Spigel, D., Grunberg, S. M., Spira, A., Janne, P. A., Joshi, V. A., McCollum, D., Evans, T. L., Muzikansky, A., Kuhlmann, G. L., Han, M., Goldberg, J. S., Settleman, J., Iafrate, A. J., Engelman, J. A., Haber, D. A., Johnson, B. E., Lynch, T. J. (2008). First-Line Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Somatic EGFR Mutations. JCO 26: 2442-2449 [Abstract] [Full Text]  
• Engelman, J. A., Janne, P. A. (2008). Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Clin. Cancer Res. 14: 2895-2899 [Abstract] [Full Text]  
• Wheatley-Price, P., Ding, K., Seymour, L., Clark, G. M., Shepherd, F. A. (2008). Erlotinib for Advanced Non-Small-Cell Lung Cancer in the Elderly: An Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. JCO 26: 2350-2357 [Abstract] [Full Text]  
• Oguri, T., Ozasa, H., Uemura, T., Bessho, Y., Miyazaki, M., Maeno, K., Maeda, H., Sato, S., Ueda, R. (2008). MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer. Molecular Cancer Therapeutics 7: 1150-1155 [Abstract] [Full Text]  
• Kim, J.-H., Bogner, P. N., Baek, S.-H., Ramnath, N., Liang, P., Kim, H.-R., Andrews, C., Park, Y.-M. (2008). Up-Regulation of Peroxiredoxin 1 in Lung Cancer and Its Implication as a Prognostic and Therapeutic Target. Clin. Cancer Res. 14: 2326-2333 [Abstract] [Full Text]  
• Kato, T., Sato, N., Takano, A., Miyamoto, M., Nishimura, H., Tsuchiya, E., Kondo, S., Nakamura, Y., Daigo, Y. (2008). Activation of Placenta-Specific Transcription Factor Distal-less Homeobox 5 Predicts Clinical Outcome in Primary Lung Cancer Patients. Clin. Cancer Res. 14: 2363-2370 [Abstract] [Full Text]  
• Laurie, S. A., Gauthier, I., Arnold, A., Shepherd, F. A., Ellis, P. M., Chen, E., Goss, G., Powers, J., Walsh, W., Tu, D., Robertson, J., Puchalski, T. A., Seymour, L. (2008). Phase I and Pharmacokinetic Study of Daily Oral AZD2171, an Inhibitor of Vascular Endothelial Growth Factor Tyrosine Kinases, in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small-Cell Lung Cancer: The National Cancer Institute of Canada Clinical Trials Group. JCO 26: 1871-1878 [Abstract] [Full Text]  
• Kumar, A., Petri, E. T., Halmos, B., Boggon, T. J. (2008). Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer. JCO 26: 1742-1751 [Abstract] [Full Text]  
• D'Addario, G., Rauch, D., Stupp, R., Pless, M., Stahel, R., Mach, N., Jost, L., Widmer, L., Tapia, C., Bihl, M., Mayer, M., Ribi, K., Lerch, S., Bubendorf, L., Betticher, D. C. (2008). Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Ann Oncol 19: 739-745 [Abstract] [Full Text]  
• Fidler, M. J., Argiris, A., Patel, J. D., Johnson, D. H., Sandler, A., Villaflor, V. M., Coon, J. IV, Buckingham, L., Kaiser, K., Basu, S., Bonomi, P. (2008). The Potential Predictive Value of Cyclooxygenase-2 Expression and Increased Risk of Gastrointestinal Hemorrhage in Advanced Non-Small Cell Lung Cancer Patients Treated with Erlotinib and Celecoxib. Clin. Cancer Res. 14: 2088-2094 [Abstract] [Full Text]  
• Silvestri, G A, Spiro, S G (2008). Carcinoma of the bronchus 60 years later. Postgrad. Med. J. 84: 182-187 [Full Text]  
• Tibaldi, C., Giovannetti, E., Vasile, E., Mey, V., Laan, A. C., Nannizzi, S., Di Marsico, R., Antonuzzo, A., Orlandini, C., Ricciardi, S., Del Tacca, M., Peters, G. J., Falcone, A., Danesi, R. (2008). Correlation of CDA, ERCC1, and XPD Polymorphisms with Response and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients. Clin. Cancer Res. 14: 1797-1803 [Abstract] [Full Text]  
• Oh, Y., Herbst, R. S., Burris, H., Cleverly, A., Musib, L., Lahn, M., Bepler, G. (2008). Enzastaurin, an Oral Serine/Threonine Kinase Inhibitor, As Second- or Third-Line Therapy of Non-Small-Cell Lung Cancer. JCO 26: 1135-1141 [Abstract] [Full Text]  
• Chiappori, A. A., Haura, E., Rodriguez, F. A., Boulware, D., Kapoor, R., Neuger, A. M., Lush, R., Padilla, B., Burton, M., Williams, C., Simon, G., Antonia, S., Sullivan, D. M., Bepler, G. (2008). Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Advanced Non-Small Cell Lung Cancer. Clin. Cancer Res. 14: 1464-1469 [Abstract] [Full Text]  
• Backlund, M. G., Amann, J. M., Johnson, D. H. (2008). Novel Strategies for the Treatment of Lung Cancer: Modulation of Eicosanoids. JCO 26: 825-827 [Full Text]  
• Edelman, M. J., Watson, D., Wang, X., Morrison, C., Kratzke, R. A., Jewell, S., Hodgson, L., Mauer, A. M., Gajra, A., Masters, G. A., Bedor, M., Vokes, E. E., Green, M. J. (2008). Eicosanoid Modulation in Advanced Lung Cancer: Cyclooxygenase-2 Expression Is a Positive Predictive Factor for Celecoxib + Chemotherapy--Cancer and Leukemia Group B Trial 30203. JCO 26: 848-855 [Abstract] [Full Text]  
• Rizvi, N. A., Riely, G. J., Azzoli, C. G., Miller, V. A., Ng, K. K., Fiore, J., Chia, G., Brower, M., Heelan, R., Hawkins, M. J., Kris, M. G. (2008). Phase I/II Trial of Weekly Intravenous 130-nm Albumin-Bound Paclitaxel As Initial Chemotherapy in Patients With Stage IV Non-Small-Cell Lung Cancer. JCO 26: 639-643 [Abstract] [Full Text]  
• Rosell, R., Robinet, G., Szczesna, A., Ramlau, R., Constenla, M., Mennecier, B. C., Pfeifer, W., O'Byrne, K. J., Welte, T., Kolb, R., Pirker, R., Chemaissani, A., Perol, M., Ranson, M. R., Ellis, P. A., Pilz, K., Reck, M. (2008). Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 19: 362-369 [Abstract] [Full Text]  
• Belani, C. P., Ramalingam, S., Perry, M. C., LaRocca, R. V., Rinaldi, D., Gable, P. S., Tester, W. J. (2008). Randomized, Phase III Study of Weekly Paclitaxel in Combination With Carboplatin Versus Standard Every-3-Weeks Administration of Carboplatin and Paclitaxel for Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer. JCO 26: 468-473 [Abstract] [Full Text]  
• Ramalingam, S. S., Dahlberg, S. E., Langer, C. J., Gray, R., Belani, C. P., Brahmer, J. R., Sandler, A. B., Schiller, J. H., Johnson, D. H. (2008). Outcomes for Elderly, Advanced-Stage Non Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599. JCO 26: 60-65 [Abstract] [Full Text]  
• Kosmidis, P. A., Kalofonos, H. P., Christodoulou, C., Syrigos, K., Makatsoris, T., Skarlos, D., Bakogiannis, C., Nicolaides, C., Bafaloukos, D., Bamias, A., Samantas, E., Xiros, N., Boukovinas, I., Fountzilas, G., Dimopoulos, M. A. (2008). Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Ann Oncol 19: 115-122 [Abstract] [Full Text]  
• Ramalingam, S., Belani, C. (2008). Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions. The Oncologist 13: 5-13 [Abstract] [Full Text]  
• Stinchcombe, T. E., Socinski, M. A. (2008). Considerations for Second-Line Therapy of Non-Small Cell Lung Cancer. The Oncologist 13: 28-36 [Abstract] [Full Text]  
• Bunn, P. A. Jr., Thatcher, N. (2008). Conclusion. The Oncologist 13: 37-46 [Abstract] [Full Text]  
• Schnipper, L. E. (2007). Update in Oncology. ANN INTERN MED 147: 775-782 [Full Text]  
• Sculier, J. P., Lafitte, J. J., Paesmans, M., Lecomte, J., Alexopoulos, C. G., Van Cutsem, O., Giner, V., Efremidis, A., Berchier, M. C., Collon, T., Meert, A. P., Scherpereel, A., Ninane, V., Koumakis, G., Vaslamatzis, M. M., Leclercq, N., Berghmans, T., for the European Lung Cancer Working Party, (2007). Chemotherapy improves low performance status lung cancer patients. Eur Respir J 30: 1186-1192 [Abstract] [Full Text]  
• Kim, D. -W., Kim, S. -Y., Kim, H. -K., Kim, S. -W., Shin, S. W., Kim, J. S., Park, K., Lee, M. Y., Heo, D. S. (2007). Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 18: 2009-2014 [Abstract] [Full Text]  
• Park, J. O., Kim, S.-W., Ahn, J. S., Suh, C., Lee, J. S., Jang, J. S., Cho, E. K., Yang, S. H., Choi, J.-H., Heo, D. S., Park, S. Y., Shin, S. W., Ahn, M. J., Lee, J. S., Yun, Y. H., Lee, J.-W., Park, K. (2007). Phase III Trial of Two Versus Four Additional Cycles in Patients Who Are Nonprogressive After Two Cycles of Platinum-Based Chemotherapy in Non Small-Cell Lung Cancer. JCO 25: 5233-5239 [Abstract] [Full Text]  
• Hohla, F., Schally, A. V., Kanashiro, C. A., Buchholz, S., Baker, B., Kannadka, C., Moder, A., Aigner, E., Datz, C., Halmos, G. (2007). Growth inhibition of non-small-cell lung carcinoma by BN/GRP antagonist is linked with suppression of K-Ras, COX-2, and pAkt. Proc. Natl. Acad. Sci. USA 104: 18671-18676 [Abstract] [Full Text]  
• Herbst, R. S., O'Neill, V. J., Fehrenbacher, L., Belani, C. P., Bonomi, P. D., Hart, L., Melnyk, O., Ramies, D., Lin, M., Sandler, A. (2007). Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non Small-Cell Lung Cancer. JCO 25: 4743-4750 [Abstract] [Full Text]